

Fetal Dilated Myocardopathy – Case Report: Association with a heterozygous mutation in *MYH7* Gene

Danielle Negri de Souza Lopes ¹, Fernanda Saraiva Bueno ¹, Marcia Cristina de Azevedo Gomes ¹, Sergio Ramos ¹, Fernando Freitas Martins ¹, Cassio Luiz de Carvalho Serão ², Maria Elisabeth Lopes Moreira ³, José Maria de Andrade Lopes ^{3,*}

¹ Neonatal Intensive Care Unit, Perinatal Maternity Hospital, Rio de Janeiro, RJ, Brazil.

² Genetics - Medical Faculty Petropolis, RJ, Brazil.

³ Neonatology of National Institute of Women's and Child's Health Fernandes Figueira, Fiocruz, RJ, Brazil.

* Correspondence: jmlopes57@gmail.com.

Abstract: We report a case of dilated myocardopathy with ascites and cardiac dysfunction detected at 20 weeks' gestation. Baby was born at 33 weeks and 6 days, weighing 2530g, delivered by cesarean section and admitted to NICU. Postnatal echocardiography confirmed biventricular severe dysfunction, need of ventilatory support, vasoactive drugs, and prostaglandins. He was investigated for metabolic, infectious, and viral diseases with no positive results. After 6 weeks, he was transferred to a transplant center. Exome sequence showed a heterozygous mutation in the *MYH7* gene (OMIN-160760.0028).

Keywords: Cardiac failure; Dilated myocardopathy; *MYH7* gene.

Citation: Lopes DNS, Bueno F, Gomes M, Ramos S, Martins FF, Serão CLCS, Moreira MEL, Lopes JMA. Fetal Dilated Myocardopathy – Case Report: Association with a heterozygous mutation in *MYH7* Gene. Brazilian Journal of Case Reports. 2024 Oct-Dec;04(4):57-60.

Received: 30 October 2023

Accepted: 25 March 2024

Published: 1 April 2024



Copyright: This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

1. Introduction

Fetal Dilated cardiomyopathy (DCM) is an infrequent disorder and accounts for a small proportion of cardiac abnormalities observed during fetal life [1]. Most cardiomyopathies recognized in utero are associated with dilated, poorly contractile left ventricles. DCM may be the result of a number of different disease processes including viral infections, metabolic disease, fetal anemia and fetal tachycardias [2].

The myosin heavy chain 7 (*MYH7*) gene encode for B-myosin, a key component of the cardiac sarcomere, and some pathogenic variants of this gene, may be associated with myocardial contractile abnormalities and dilated cardiomyopathies. Pathogenic variants in *MYH7* have been described in 1 to 5% of DCM cases [3].

Several publications have described the possible association of cardiomyopathies to mutations in the *MYH7* gene. Catrina et al described 3 different phenotypes associated with this gene including a dilated form of cardiomyopathy [3, 4]. The annual incidence of cardiomyopathies in childhood is around 1.2 for each 100.000 children. More than 40 per cent of affected children ultimately die or require cardiac transplantation [3].

2. Case Report

A 33-year-old primiparous Brazilian woman who had an uneventful antenatal course until 34 weeks of gestation. She was referred to our tertiary center due to diagnosis of dilated myocardopathy with ascites and cardiac dysfunction detected at fetal ultrasonography. There was no previous family history of cardiac disease. A male neonate weighing

2530g was delivered by C-section with Apgar scores of 8 at 1 min, and 9 at 5 minutes. The baby was electively intubated in the delivery room and transferred to NICU.

Mechanical ventilation with support parameters was initiated, as well as adrenaline and milrinone infusions. First echocardiography showed severe biventricular dysfunction, moderate to severe tricuspid regurgitation, mild mitral regurgitation, and patent ductus arteriosus with L-R shunt. Laboratory tests were negative for viral and bacterial diseases and metabolic screening (Tandem Mass Spectrometry) was also negative. In the tenth day, baby presented a positive urine culture and was started on antibiotics. A trial with 3 doses of Levozimedan was attempted with 11 days of age with small improvements in cardiac function.

With 12 days, he was extubated for nasal CPAP. A genetic consult indicated a karyotype and DNA extraction, looking for markers of a genetic disorder. A cardiac magnetic resonance showed a biventricular systolic dysfunction (FE LV 12% e RV 22%) without myocardial necrosis or fibrosis and no evidence of metabolic disease. At 16 days of life, cardiorespiratory condition deteriorated, and baby was re-intubated. Echocardiography still showing an important mitral, tricuspid, and pulmonary regurgitation with PAP 70-75%. Baby was started on furosemide. At 19 days, a new cycle of Levozimedan was initiated. At the 25th day echocardiography showed the same findings of severe myocardial dysfunction (FE LV 17% e RV 20%) (Figure 1)

At 30 days, baby was transfused for anemia and started on antibiotics because of another positive urine culture. Clexane was started for the possibility of intramural cardiac thrombosis. Results of new generation genome sequencing identified a heterozygous mutation in the *MYH7* gene (OMIM-160760.0028). Both parents tested negative for the mutation. This analysis was performed with an Illumina sequencer, with reference to the GRCh38 genome version, with processing of the BAM files aligned by the Exome Depth program (<https://cran.rproject.org/web/packages/ExomeDepth/index.html>), and allele frequency analysis by GnomAD. They also report that the sequencing resulted in a percentage of target bases with at least 10 readings: 99.9%, Average number of times each database was read: 82 and Number of sequences generated: 34,426,793. The name of the variant is Chr14:23.432.666 C>T T (or alternatively c.475G>A - ENST00000355349), which results in a missense mutation with the exchange of the amino acid aspartate at codon 159 for an asparagine (p. Asp159Asn).

As clinical condition was worsening, with no significant improvement in cardiac function and moderate response to several attempted medications, family agreed to transfer the baby to a transplant center and offer a possible therapeutic option. In the subsequent weeks, baby progressively stabilized and was discharged home. Baby is now two years of age, has been submitted to heart transplantation and is at home, in a stable clinical condition.


3. Discussion and conclusions

We describe a case of Dilated Cardiomyopathy, possibly associated to *MYH7* gene. Fetal evaluation showed ascites and cardiac dysfunction at 20 weeks gestation. After birth, baby showed signs of heart failure, with biventricular dysfunction and very low ejection fractions. The possibility of infectious diseases was excluded by diagnostic tests and the genetic evaluation showed a heterozygous mutation in the *MYH7* gene. The myosin heavy chain (*MYH*) genes are a family of genes that encode for proteins that are involved in muscle contraction. Defects or mutations in these genes can lead to a variety of muscle-related disorders [3]. There are several different *MYH* genes, each of which is associated with a different type of muscle tissue. *MYH7* is primarily expressed in cardiac muscle, and mutation in this gene has been associated with several cardiac conditions, including hypertrophic cardiomyopathy, dilated cardiomyopathy and left ventricular noncompaction.

Several reports have associated cardiomyopathies with this mutation. Kamisago et al [5, 6] describe a family with dilated cardiomyopathy with a mutation in beta-myosin

heavy chain gene, where one member had received cardiac transplant at 23 years of age and a female child developed congestive heart failure at 2 years of age. In other report, another family with *MYH* mutation where the father was given the diagnosis of cardiomyopathy at 11 years of age and a daughter died suddenly at the age of 2 months. A 4-year-old daughter, diagnosed with dilated cardiomyopathy at the time of birth, was found to have fetal left ventricular dilatation.

Figure 1. A. Apical Four Chamber View showing marked enlargement of all cardiac chambers mainly of left ventricle. B. Longa Axis Parasternal View showing marked enlarged left ventricle. C. Ejection Fraction severely compromised (17%). D. Severe Mitral Regurgitation due to ventricle dilatation.



In a series of 46 young patients with dilated cardiomyopathy Beecroft et al. identified 2 mutations in the *MYH7* gene. One patient with this mutation was 35 years old when diagnosed with dilated cardiomyopathy and the other was 18 years old when diagnosed with dilated cardiomyopathy [7]. The *MYH7* gene encodes the beta-cardiac/slow skeletal myosin heavy chain (MYHC-slow), expressed predominantly in the cardiac ventricles and slow skeletal (type 1) myofibers. Myosin acts as a molecular motor through its interaction with actin of the thin filament, which is vital for skeletal muscle force generation [4].

In 2020, Kuo et al described in a case report a Fetal Dilated Cardiomyopathy associated with variants of uncertain significance in *MYH7* and *DSG2* genes. Diagnosis was made at 31 weeks of age several weeks after a maternal flu-like disease. Although maternal Coxsackie virus titers were elevated post-natal cord blood was negative. Genetic testing for DCM demonstrated heterozygous variants of uncertain significance in the *MYH7* and *DSG2* genes, exactly as our case. Baby required temporary inotropic support but at the age of two years an echocardiogram showed normal biventricular function [8].

Dilated cardiomyopathy diagnosed in fetal life can be a consequence of variety of conditions, including, infectious, metabolic, renal, and genetic diseases [8-11]. Transition from fetal life is characterized by important hemodynamic changes particularly in infants with DCM, who will require NICU admission for stabilization and proper diagnosis. Our patient was non-responsive to inotropic drugs but remained hemodynamically stable using diuretics during the neonatal period even with a very compromised cardiac function.

We report a very severe case of DCM, not associated with metabolic, infectious, or renal diseases, who required several weeks of newborn intensive care, with a very low ejection fraction and critical condition. Genetic testing showed a heterozygous mutation in the *MYH7* gene, initially thought as of uncertain significance, but probably pathogenic, with both parents testing negative for this mutation and no family reported cases of DCM. Our report may add some evidence of the association of DCM with *MYH7* mutation.

Funding: None.

Research Ethics Committee Approval: Information about baby's clinical condition as well as the results of tests can be accessed through the medical records of the Perinatal Maternity Hospital (Rio de Janeiro) and Israelita Albert Einstein Hospital (São Paulo), where he underwent clinical treatment and heart transplant.

Acknowledgments: None.

Conflicts of Interest: None.

Supplementary Materials: None.

References

1. Allan LD, Sharland GK, Milburn A, et al. Prospective diagnosis of 1006 consecutive cases of congenital heart disease in the fetus. *J Am Coll Cardiol.* 1994;23(6):1445-1458.
2. Sivasubramonian S, Gurleen KS, Simpson JM. Dilated cardiomyopathy presenting during fetal life. *Cardiol Young.* 2003;15(4):409-416.
3. Jordan E, Peterson L, Ai T, et al. Evidence-based assessment of genes in dilated cardiomyopathy. *Circulation.* 2021;144(1):7-19.
4. Frutos F, Ochoa JP, Navarro Penalver M, Bass A, et al. Natural history of MYH-related dilated cardiomyopathy. *Circulation.* 2022;80(5):1447-1461.
5. Catrina BI, Batar F, Baltat G, Bitea CI, Puia A, Stoia O, Fleaca SR, Teodoru M. A family with MYH7 mutation and different forms of cardiomyopathies. *Biomedicines.* 2023;11:2065. Available from: <https://doi.org/10.3390/biomedicines11072065>
6. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, Smoot L, Mullen MP, Woolf PK, Wigle ED, Seidman JG, Seidman CE. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. *N Engl J Med.* 2000;343(23):1688-1696.
7. Beecroft SJ, van de Locht M, de Winter JM, Ottenheijm CA, Sewry CA, Mohammed S, Ryan MM, Woodcock IR, Sanders L, Gooding R, Davis MR, Oates EC, Laing NG, Ravenscroft G, McLean CA, Jungbluth HR. Recessive MYH7-related myopathy in two families. *Neuromuscul Disord.* 2019;29(6):456-467.
8. Kelly K, Speranza R, Hackmon R. Fetal dilated cardiomyopathy associated with variants of uncertain significance in MYH7 and DSG2 genes: a case report and review of the literature. *J Obstet Gynaecol Can.* 2020;42(9):1147-1150.
9. Daehmlow S, Erdmann J, Knueppel T, Gille C, Froemmel C, Hummel M, Hetzer R, Regitz-Zagrosek V. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. *Biochem Biophys Res Commun.* 2002;298(1):116-120.
10. Yinon Y, Yagel S, Hegesh J, Weisz B, et al. Fetal cardiomyopathy: in utero evaluation and clinical significance. *Prenat Diagn.* 2007;27(1):23-28.
11. Pedra SRF, Smallhorn JF, Ryan G, Chitayat D, et al. Fetal cardiomyopathies: pathogenic mechanisms, hemodynamic findings, and clinical outcome. *Circulation.* 2002;106(5):585-591.